Multidomain Enzyme Protein for CD63-Mediated Lysosomal Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapies for lysosomal storage diseases suffer from poor targeting of replacement enzymes to relevant tissues, negative immunological reactions, and low serum half-life, leading to inadequate treatment outcomes.
Innovation Solution
Development of a multidomain therapeutic protein comprising a delivery domain, such as an antigen-binding protein that binds to CD63, and an enzyme domain, like alpha-glucosidase, delivered via a gene therapy vector, which enhances tissue biodistribution and lysosomal uptake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is administered, then enzyme activity is restored in lysosomes, but poor targeting to relevant tissues occurs
Solution Approach 1:
The patent employs the mannose-6-phosphate (M6P) receptor as an intermediary to mediate the delivery of replacement enzymes to lysosomes. The M6P receptor recognizes and binds to M6P-tagged enzymes, facilitating their transport into the lysosome. This intermediary mechanism solves the targeting problem by providing a specific recognition system that directs enzymes to the correct intracellular destination.
Solution Approach 2:
The patent modifies the enzymatic protein by adding mannose-6-phosphate tags to its structure. This parameter change (adding specific molecular tags) enables the enzyme to be recognized by M6P receptors, thereby changing its cellular trafficking parameters and ensuring proper delivery to lysosomes while improving tissue targeting efficiency.
2Reliability
If high dose enzyme replacement therapy is administered, then enzyme activity is restored, but negative immunological reactions occur
Solution Approach 1:
The patent modifies the immunogenic parameters of the replacement enzyme by adding M6P tags and optimizing its structural parameters. These changes reduce the immunogenicity of the therapeutic enzyme, allowing for effective enzyme activity restoration with minimal immunological reactions, thus resolving the contradiction between efficacy and immune tolerance.
3Productivity
If frequent high dose enzyme replacement therapy is administered, then substrate degradation is improved, but serum half-life is reduced
Solution Approach 1:
The patent optimizes the structural and biochemical parameters of the replacement enzyme, including adding M6P tags and modifying amino acid sequences. These parameter changes enhance the enzyme's stability and serum half-life, allowing for less frequent administration while maintaining effective substrate degradation, thus resolving the contradiction between productivity and duration of action.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multidomain therapeutic protein effectively delivers enzymes to target cells, reducing glycogen accumulation and restoring enzyme activity in tissues, while minimizing immunological reactions and maintaining serum levels for extended periods.
Implementation Method 1
a delivery domain, such as an antigen-binding protein that binds to CD63
Implementation Method 2
enhances tissue biodistribution and lysosomal uptake
Data Source
Figure 1AA(i)~1AH
Figure 1B
Figure 2
AI summary
Compositions and methods for treating enzyme-deficiency diseases are disclosed. Multidomain therapeutic proteins containing an internalization effector binding domain and a lysosomal replacement enzyme activity are disclosed. The multidomain therapeutic proteins are capable of entering cells, segregating to the lysosome, and delivering the replacement enzyme activity to the lysosome.